Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000229836, known as the “novel HLA class I pseudogene fragment,” is a human pseudogene fragment located in the major histocompatibility complex (MHC) Class I region. Pseudogenes in this region are non-functional remnants of previously active HLA class I-related genes, arising through gene duplications and subsequent mutations. This particular fragment shares sequence homology with the HLA class I family, which encompasses highly polymorphic molecules essential for antigen presentation in the immune system, but it lacks protein-coding potential or known physiological function. It does not encode a protein, is not considered a therapeutic target, and has no direct disease associations, biomarker value, or safety concerns. This pseudogene and others in the HLA class I region are studied primarily for evolutionary insight into the structure and diversification of the HLA gene family and do not participate in immune signaling or disease pathways.
None (not a protein-coding or functional regulatory gene)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel HLA class I pseudogene fragment (ENSG00000229836).